Latest Biotechnology News

Page 8 of 115
Racura Oncology says both Phase 1 RC220 programs have cleared their opening dose cohorts without dose-limiting toxicities, while its Korean expansion broadens the CPACS trial. The company ended September with $30.7 million in cash, which management says funds committed activities into mid-2028.
Victor Sage
Victor Sage
22 Oct 2026
Recce Pharmaceuticals has granted Arrotex exclusive rights to commercialise its investigational RECCE 327 topical gel in Australia and New Zealand. The agreement offers a potential profit-share stream, but no upfront payments, sales forecast or approval have been disclosed.
Ada Torres
Ada Torres
22 Oct 2026
Arovella Therapeutics has received a $4.03 million FY2026 R&D tax refund, giving the clinical-stage biotech additional cash as it advances its lead therapy ALA-101 towards first-patient dosing. The payment arrives without any accompanying clinical data or disclosed update to the company’s cash runway.
Ada Torres
Ada Torres
22 Oct 2026
Avecho Biotechnology has told the ASX it is unaware of any undisclosed information that could explain a sharp move in its share price and a significant increase in trading volume. The company also confirmed compliance with continuous disclosure rules after responding to an exchange price query.
Ada Torres
Ada Torres
21 Oct 2026
Invion has secured two financing arrangements that could cover up to approximately 85% of its clinical trial costs, providing support for its skin cancer and planned anogenital cancer programs. The funding comes with potential dilution, 16% interest and conditions that leave the actual amount available dependent on drawdowns and R&D tax refunds.
Victor Sage
Victor Sage
21 Oct 2026
Recce Pharmaceuticals says a review of blinded Phase 3 data for its RECCE 327 Gel showed strong efficacy and a positive safety profile. An independent committee is expected to assess unblinded data from 75 patients as soon as mid-November, while recruitment continues.
Ada Torres
Ada Torres
20 Oct 2026
Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.
Ada Torres
Ada Torres
20 Oct 2026
Microba has secured a $2.025 million placement while cutting costs further, launching GI Navigator and advancing its proposed merger with Genetic Signatures. The funding comes as the company reports strong Australian testing growth but only about one quarter of cash cover before the raise.
Victor Sage
Victor Sage
20 Oct 2026
Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.
Ada Torres
Ada Torres
19 Oct 2026
Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.
Ada Torres
Ada Torres
19 Oct 2026
Zoono Group has advanced retailer, packaging and shipping-container programs across several markets, but ended the September quarter with just NZ$77,000 in cash. The company estimates funding for 0.67 quarters and says further funding lines or an equity raise may be required if customer receipts do not accelerate.
Ada Torres
Ada Torres
19 Oct 2026
AdAlta expects an additional R&D Tax Incentive refund of more than A$1 million after securing approval for specified overseas work on its EW-001 CAR-T therapy. The cash benefit arrives as the company prepares for a US FDA pre-IND meeting in November.
Ada Torres
Ada Torres
19 Oct 2026

Browse the archive

Full archive